

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/116001 A1

(51) International Patent Classification⁷: **C07D 277/30**,
417/06, 417/04, A61K 31/426, 31/427, A61P 11/06

[NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970
Hoersholm (DK).

(21) International Application Number:
PCT/EP2005/005882

(74) Agent: **WALLS, Alan, James**; P.O. Box 223, Tadworth,
Surrey KT20 5SS (GB).

(22) International Filing Date: 30 May 2005 (30.05.2005)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0412198.4 29 May 2004 (29.05.2004) GB
0414194.1 24 June 2004 (24.06.2004) GB
0424016.4 29 October 2004 (29.10.2004) GB

(71) Applicant (for all designated States except US): **7TM
PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2970 Ho-
ersholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ULVEN, Trond**
[NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970
Hoersholm (DK). **FRIMURER, Thomas** [DK/DK]; 7TM
Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK).
RIST, Øystein [NO/DK]; 7TM Pharma A/S, Fremtidsvej
3, DK-2970 Hoersholm (DK). **KOSTENIS, Evi** [DE/DK];
7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm
(DK). **HÖGBERG, Thomas** [SE/SE]; 7TM Pharma A/S,
Fremtidsvej 3, DK-2970 Hoersholm (DK). **RECEVEUR,
Jean-Marie** [FR/DK]; 7TM Pharma A/S, Fremtidsvej
3, DK-2970 Hoersholm (DK). **GRIMSTRUP, Marie**


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED THIAZOLEACETIC AS CRTH2 LIGANDS



(57) Abstract: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X₁ is -S-, -O-, -N=N-, -NR₇-, -CR₇=CR₈-, -CR₇=N-, wherein R₇ and R₈ are independently hydrogen or C₁-C₃ alkyl; A is a carboxyl group -COOH, or a carboxyl bioisostere; rings Ar² and Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar² and Ar³, or an optionally substituted N-pyrrolidiny, N-piperidiny or N-azepiny ring; s is 0 or 1; L₁, L₂ and L₄ are linker radicals as defined in the description; Q₁ and Q₂ represent substituents as defined in the description.